These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17524347)

  • 41. [Hyperprolactinemia: causes, diagnosis, and treatment].
    Karasek M; Pawlikowski M; Lewiński A
    Endokrynol Pol; 2006; 57(6):656-62. PubMed ID: 17253440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Functional characterization of hypothalamic hyperprolactinemia.
    Ferrari C; Rampini P; Benco R; Caldara R; Scarduelli C; Crosignani PG
    J Clin Endocrinol Metab; 1982 Nov; 55(5):897-901. PubMed ID: 6811605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia.
    Le Moli R; Endert E; Fliers E; Prummel MF; Wiersinga WM
    Neth J Med; 2003 Feb; 61(2):44-8. PubMed ID: 12735420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Macroprolactinemia in women with hyperprolactinemia: a 10-year follow-up.
    Radavelli-Bagatini S; Lhullier FL; Mallmann ES; Spritzer PM
    Neuro Endocrinol Lett; 2013; 34(3):207-11. PubMed ID: 23685418
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Macroprolactinemia associated with pituitary macroadenoma: treatment with quinagolide].
    Lakatos G; Szücs N; Kender Z; Czirják S; Rácz K
    Orv Hetil; 2010 Jun; 151(26):1072-5. PubMed ID: 20558354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The hook effect in prolactin immunoassays.
    Al Sifri SN; Raef H
    Saudi Med J; 2004 May; 25(5):656-9. PubMed ID: 15138537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.
    Tamer G; Telci A; Mert M; Uzum AK; Aral F; Tanakol R; Yarman S; Boztepe H; Colak N; Alagöl F
    Endocrine; 2012 Feb; 41(1):138-43. PubMed ID: 21959531
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MRI--diagnostic and follow-up tool for microprolactinomas.
    Seidl Z; Obenberger J; Marek J; Hána V; Vanĕcková M
    Funct Neurol; 2000; 15(1):47-51. PubMed ID: 10842760
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determination of the frequency of hyperprolactinemia-related etiologies and the etiology-specific mean prolactin levels.
    Korkmaz FN; Gökçay Canpolat A; Şahin M; Çorapçioğlu D
    Minerva Endocrinol (Torino); 2021 Sep; ():. PubMed ID: 34528777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The importance of macroprolactinemia in the differential diagnosis of hyperprolactinemic patients.
    Bağdatoğlu C; Bağdatoğlu OT; Muslu N; Köseoğlu A; Dağtekin A; Polat G; Dolgun H; Karataş MA
    Turk Neurosurg; 2008 Jul; 18(3):223-7. PubMed ID: 18814107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases.
    Wang M; Mou C; Jiang M; Han L; Fan S; Huan C; Qu X; Han T; Qu Y; Xu G
    Eur J Endocrinol; 2012 May; 166(5):797-802. PubMed ID: 22334636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The proportion of glycosylated prolactin in serum is decreased in hyperprolactinemic states.
    Hashim IA; Aston R; Butler J; McGregor AM; Smith CR; Norman M
    J Clin Endocrinol Metab; 1990 Jul; 71(1):111-5. PubMed ID: 2370290
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Influence of hyperprolactinemia and tumoral size in the postoperative pituitary function in clinically nonfunctioning pituitary macroadenomas].
    Fonseca AL; Chimelli L; Santos MJ; Santos AA; Violante AH
    Arq Neuropsiquiatr; 2002 Sep; 60(3-A):590-602. PubMed ID: 12244397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prolactin response to clomiphene citrate is different in hyperprolactinemic polycystic ovary syndrome and idiopathic hyperprolactinemia.
    Lewinthal D; Corenblum B; Taylor PJ
    Int J Fertil; 1987; 32(3):185-7, 191. PubMed ID: 2885281
    [No Abstract]   [Full Text] [Related]  

  • 56. Diagnosis of stress-related hyperprolactinemia. Evaluation of the hyperprolactinemia rest test.
    Muneyyirci-Delale O; Goldstein D; Reyes FI
    N Y State J Med; 1989 Apr; 89(4):205-8. PubMed ID: 2733871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicentric experience on the acute effect of nomifensine in hyperprolactinemic women.
    Minuto F; Barbarino A; Baviera G; Mazzocchi G; De Marinis L; Leonardi R; Bernasconi D; Menini E; Maira G; Anile C
    J Endocrinol Invest; 1984 Apr; 7(2):137-40. PubMed ID: 6725869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hyperprolactinemia: different clinical expression in childhood.
    Saranac L; Zivanovic S; Radovanovic Z; Kostic G; Markovic I; Miljkovic P
    Horm Res Paediatr; 2010; 73(3):187-92. PubMed ID: 20197671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced dopaminergic inhibition of thyrotropin release in hyperprolactinemic ovulatory women.
    Larrea F; Escorza A; Valencia X; Méndez I; Schiavon R; Forsbach G
    Rev Invest Clin; 1991; 43(4):293-8. PubMed ID: 1798861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Approach to the patient with persistent hyperprolactinemia and negative sellar imaging.
    Glezer A; Bronstein MD
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2211-6. PubMed ID: 22774208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.